
Hematological Malignancies Market by Types (Leukemia, Lymphoma, Multiple Myeloma), Treatment (Bone Marrow Transplantation, Chemotherapy, Chimeric Antigen Receptor (Car) T Cell Therapy), Diagnosis, End-Users - Global Forecast 2024-2030
Description
Hematological Malignancies Market by Types (Leukemia, Lymphoma, Multiple Myeloma), Treatment (Bone Marrow Transplantation, Chemotherapy, Chimeric Antigen Receptor (Car) T Cell Therapy), Diagnosis, End-Users - Global Forecast 2024-2030
The Hematological Malignancies Market size was estimated at USD 15.33 billion in 2023 and expected to reach USD 16.84 billion in 2024, at a CAGR 9.92% to reach USD 29.73 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Hematological Malignancies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hematological Malignancies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Hematological Malignancies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Limited, Adcendo ApS, Amgen Inc., Artiva Biotherapeutics, Inc., Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company, Dren Bio, Inc., F. Hoffmann-La Roche AG, Geron Corporation, GlaxoSmithKline PLC, Harpoon Therapeutics, Inc., Immune-Onc Therapeutics, Inc., Interius BioTherapeutics, Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Kirilys Therapeutics, Inc., Kymera Therapeutics, MEI Pharma, Inc., Merck & Co., Inc., Moleculin Biotech, Inc., NovalGen Ltd., Novartis AG, Oncoternal, Pfizer Inc., Prelude Therapeutics Incorporated, Reverie Labs Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, TG Therapeutics, Inc., and Tvardi Therapeutics, Inc..
Market Segmentation & Coverage
This research report categorizes the Hematological Malignancies Market to forecast the revenues and analyze trends in each of the following sub-markets:
Types
Leukemia
Lymphoma
Multiple Myeloma
Treatment
Bone Marrow Transplantation
Chemotherapy
Chimeric Antigen Receptor (Car) T Cell Therapy
Immunotherapy
Targeted Therapy
Diagnosis
Biopsy
Blood Tests
Imaging Tests
End-Users
Homecare
Hospitals
Specialty Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Hematological Malignancies Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hematological Malignancies Market?
3. What are the technology trends and regulatory frameworks in the Hematological Malignancies Market?
4. What is the market share of the leading vendors in the Hematological Malignancies Market?
5. Which modes and strategic moves are suitable for entering the Hematological Malignancies Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Hematological Malignancies Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of hematological cancer cases
- 5.1.1.2. Rising awareness about the possibility of early diagnosis
- 5.1.1.3. Favorable regulatory environment and government support for therapies
- 5.1.2. Restraints
- 5.1.2.1. Lack of awareness and huge cost associated with hematological malignancies treatment
- 5.1.3. Opportunities
- 5.1.3.1. Rising investment in the development of advanced hematological malignancies treatment
- 5.1.3.2. Surging drug approvals and launches of novel hematological malignancies drugs
- 5.1.4. Challenges
- 5.1.4.1. Dearth of skilled professionals and side effects of hematological malignancies therapies
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Hematological Malignancies Market, by Types
- 6.1. Introduction
- 6.2. Leukemia
- 6.3. Lymphoma
- 6.4. Multiple Myeloma
- 7. Hematological Malignancies Market, by Treatment
- 7.1. Introduction
- 7.2. Bone Marrow Transplantation
- 7.3. Chemotherapy
- 7.4. Chimeric Antigen Receptor (Car) T Cell Therapy
- 7.5. Immunotherapy
- 7.6. Targeted Therapy
- 8. Hematological Malignancies Market, by Diagnosis
- 8.1. Introduction
- 8.2. Biopsy
- 8.3. Blood Tests
- 8.4. Imaging Tests
- 9. Hematological Malignancies Market, by End-Users
- 9.1. Introduction
- 9.2. Homecare
- 9.3. Hospitals
- 9.4. Specialty Clinics
- 10. Americas Hematological Malignancies Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Hematological Malignancies Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Hematological Malignancies Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. AbbVie Inc.
- 14.1.2. Adaptimmune Limited
- 14.1.3. Adcendo ApS
- 14.1.4. Amgen Inc.
- 14.1.5. Artiva Biotherapeutics, Inc.
- 14.1.6. Atara Biotherapeutics, Inc.
- 14.1.7. Bristol-Myers Squibb Company
- 14.1.8. Dren Bio, Inc.
- 14.1.9. F. Hoffmann-La Roche AG
- 14.1.10. Geron Corporation
- 14.1.11. GlaxoSmithKline PLC
- 14.1.12. Harpoon Therapeutics, Inc.
- 14.1.13. Immune-Onc Therapeutics, Inc.
- 14.1.14. Interius BioTherapeutics, Inc.
- 14.1.15. Johnson & Johnson Services, Inc.
- 14.1.16. Karyopharm Therapeutics Inc.
- 14.1.17. Kirilys Therapeutics, Inc.
- 14.1.18. Kymera Therapeutics
- 14.1.19. MEI Pharma, Inc.
- 14.1.20. Merck & Co., Inc.
- 14.1.21. Moleculin Biotech, Inc.
- 14.1.22. NovalGen Ltd.
- 14.1.23. Novartis AG
- 14.1.24. Oncoternal
- 14.1.25. Pfizer Inc.
- 14.1.26. Prelude Therapeutics Incorporated
- 14.1.27. Reverie Labs Inc.
- 14.1.28. Sanofi S.A.
- 14.1.29. Takeda Pharmaceutical Company Limited
- 14.1.30. TG Therapeutics, Inc.
- 14.1.31. Tvardi Therapeutics, Inc.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. HEMATOLOGICAL MALIGNANCIES MARKET RESEARCH PROCESS
- FIGURE 2. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2023 VS 2030
- FIGURE 3. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HEMATOLOGICAL MALIGNANCIES MARKET DYNAMICS
- FIGURE 7. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2023 VS 2030 (%)
- FIGURE 8. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 10. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
- FIGURE 12. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 14. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.